Retatrutide for Knee Osteoarthritis: The TRIUMPH-4 Results

Osteoarthritis of the knee is the most common form of arthritis and a leading cause of disability worldwide. Obesity is one of its strongest modifiable risk factors — every pound of body weight translates to approximately 4 pounds of pressure on the knee joint. Weight loss has long been recommended as a first-line intervention, but achieving the magnitude of weight loss needed to meaningfully reduce symptoms has been difficult without surgery.

TRIUMPH-4 Trial Design

Baseline characteristics

• Mean body weight: 112.7 kg
• Mean BMI: 40.4
• 84% had BMI of 35 or higher (Class 2 or 3 obesity)
• Mean baseline WOMAC pain score: 6.0 points (on a 0-10 scale)

The WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) is the standard validated instrument for measuring osteoarthritis symptoms. It assesses pain, stiffness, and physical function. The baseline pain score of 6.0 indicates moderate-to-severe knee pain.

Weight Loss Results

Knee Pain and Physical Function Results

WOMAC pain score

Complete pain resolution

These pain-free percentages came from a post-hoc analysis of observed efficacy-estimand data. They describe reported pain at the assessment, not evidence of cartilage repair.

• 14.1% of 9mg participants and 12.0% of 12mg participants were completely free of knee pain at 68 weeks
• This compared to 4.2% on placebo
• Complete pain resolution is a high bar — it represents the elimination of all knee osteoarthritis pain, not merely an improvement

WOMAC physical function

Physical function improvements paralleled the pain reductions, indicating that the benefits translated to real-world ability to perform daily activities — walking, climbing stairs, standing, and bending.

Cardiovascular and Metabolic Improvements

How Weight Loss Affects Knee Osteoarthritis

Weight loss may relieve knee symptoms through reduced mechanical loading and metabolic changes. TRIUMPH-4 did not isolate how much of the pain improvement was due to each mechanism.

Mechanical load

The trial measured body weight, pain, and physical function. It did not report a per-step reduction in knee force, so the average pounds lost should not be converted into a patient-specific joint-load figure. Nor do pain improvements establish that cartilage damage was reversed.

Systemic inflammation

• Obesity is associated with chronic low-grade inflammation, driven by adipose tissue (fat cells) secreting pro-inflammatory cytokines
• These inflammatory mediators contribute to cartilage degradation and joint pain beyond what mechanical loading alone explains
• Weight loss reduces adipose tissue-derived inflammation, as reflected in the hsCRP improvements seen in TRIUMPH-4

Why the 9mg and 12mg results were similar for pain

Safety and Adverse Events

The adverse event profile in TRIUMPH-4 was consistent with the GLP-1 drug class:

What This Means for Osteoarthritis Treatment

A potential new paradigm

Currently, the treatment options for obesity-related knee osteoarthritis are limited:

• Lifestyle modification — effective but difficult to sustain at the required magnitude
• Physical therapy — improves function and pain but does not address the root cause of excess weight
• NSAIDs and analgesics — symptom management only, with their own side effect risks
• Corticosteroid or hyaluronic acid injections — temporary relief
• Knee replacement surgery — effective but invasive, costly, and often deferred in younger patients

A drug that simultaneously addresses the root cause (obesity) and produces substantial symptom relief could reshape treatment algorithms for obesity-related osteoarthritis.

Regulatory implications

Eli Lilly has stated it plans to include the TRIUMPH-4 osteoarthritis data in its regulatory submissions. If approved, retatrutide could receive a specific indication for weight management in adults with obesity and knee osteoarthritis — similar to how Zepbound received an OSA indication.

TRIUMPH-4 was designed with two co-primary endpoints to support both a weight-management indication and a pain-relief indication for knee osteoarthritis. Both were met — opening a path to two regulatory filings from a single trial.

What Comes Next

• Full peer-reviewed publication of TRIUMPH-4 is expected with additional secondary endpoints and body composition data.
• Combined with TRANSCEND-T2D-1 (Mar 2026), TRIUMPH-1 (May 2026), and TRIUMPH-2 plus TRIUMPH-3 (both July 23, 2026), five major retatrutide Phase 3 trials have now reported.
• Still outstanding: TRIUMPH-5 (head-to-head vs tirzepatide), TRIUMPH-6 (weight maintenance), and the MASH / MASLD readouts.
• FDA filing: Lilly said on July 23, 2026 that it plans to submit a Biologics License Application in Q1 2027, supporting obesity, knee OA, and OSA indications. See our FDA approval timeline.

Frequently Asked Questions

Sources

• Jastreboff, A.M., et al. (2023). Phase 2 obesity trial, including sensory adverse events
• Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release.
• ClinicalTrials.gov: NCT05931367
• Messier, S.P., et al. (2004). Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis. Arthritis & Rheumatism.